NCT04931420 is a Phase 2 clinical trial of Standard of Care Chemotherapy in Metastatic Cancer, sponsored by University of Chicago.

Who is sponsoring NCT04931420?

NCT04931420 is sponsored by University of Chicago.

What drugs are being tested in NCT04931420?

Interventions in NCT04931420: Standard of Care Chemotherapy, Video-Assisted Thoracic Surgery (VATS), Lobectomy, Consolidative Radiation, Ablation Treatment, Resection or Excision, Peritonectomy, Transarterial Radioembolization.

What condition does NCT04931420 study?

NCT04931420 studies Metastatic Cancer, Foregut Carcinoid Tumor, Gastric Adenocarcinoma, Gallbladder Adenocarcinoma, Liver Cancer, GI Cancer, GI Carcinoma, Lung Cancer.

Is NCT04931420 still recruiting?

NCT04931420 is currently withdrawn. Last updated 31 July 2024.

Last reviewed 2024-07-31 · How we verify

NCT04931420

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

Withdrawn Phase 2 Last updated 31 July 2024

What this trial tests

Phase 2 trial testing Standard of Care Chemotherapy in Metastatic Cancer. Withdrawn.

Timeline

19 May 2022

Primary endpoint
1 May 2026

1 November 2027

Quick facts

Lead sponsor	University of Chicago
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	treatment
Start date	19 May 2022
Primary completion	1 May 2026
Estimated completion	1 November 2027

Drugs / interventions tested

Standard of Care Chemotherapy — full drug profile →
Video-Assisted Thoracic Surgery (VATS)
Lobectomy
Consolidative Radiation
Ablation Treatment
Resection or Excision
Peritonectomy
Transarterial Radioembolization

Conditions studied

Metastatic Cancer — all drugs for Metastatic Cancer →
Foregut Carcinoid Tumor — all drugs for Foregut Carcinoid Tumor →
Gastric Adenocarcinoma — all drugs for Gastric Adenocarcinoma →
Gallbladder Adenocarcinoma — all drugs for Gallbladder Adenocarcinoma →

Sponsor

University of Chicago

Who can join

18 and older, any sex, with Metastatic Cancer or Foregut Carcinoid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed for participants who have cancer of the upper gastrointestinal (GI) tract such as cancer of the esophagus, stomach, duodenum (the initial portion of your small intestine), pancreas, bile duct (Cholangiocarcinoma), ampulla, or gall bladder with limited sites of spread (metastases). Doctors leading this study are looking to see if treating the disease using sequential procedures (more than one procedure given one after another) such as surgeries or radiation can lead to better survival and if these surgeries, combined with standard of care treatment, are safe for the treatment of upper GI cancers.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA
Dhiman A, Vining CC, Witmer HDD, Sood D, et al · · 2022 · cited 7× · PMID 34988836 · DOI 10.1245/s10434-021-11249-7
Integration of circulating tumor DNA in biliary tract cancer: the emerging landscape.
Awosika JA, Monge C, Greten TF. · · 2024 · cited 6× · PMID 39881555 · DOI 10.1080/20450923.2024.2403334
The evolving concept of conversion surgery for upfront unresectable upper gastrointestinal and hepato-pancreato-biliary cancers: comprehensive review.
Perri G, Engstrand J, Wright RD, Bronzwaer SFC, et al · · 2025 · cited 1× · PMID 40631805 · DOI 10.1093/bjsopen/zraf070

Verify or expand the search:

Other trials of Standard of Care Chemotherapy

Trials testing the same drug.

NCT06937905 — Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic P · Phase 3 · recruiting
NCT07001748 — Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With G · Phase 2, PHASE3 · recruiting
NCT06044311 — Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma · Phase 2 · recruiting
NCT04973137 — A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis · Phase 3 · terminated
NCT04620681 — CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML · Phase 1, PHASE2 · completed

Other recruiting trials for Metastatic Cancer

Currently open trials in the same condition.

NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
NCT07144085 — Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases. · Phase 1 · recruiting
NCT06963723 — Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer · NA · recruiting
NCT06311851 — Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases · Phase 1, PHASE2 · recruiting
NCT07011862 — COBRA: Cancer, Older Adults, Balance and Resistance Activities · NA · recruiting

Other University of Chicago trials

Trials by the same sponsor.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04931420 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Chicago
Last refreshed: 31 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04931420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing